Exo is pairing its ultrasound device with workflow apps to provide hospitals and clinics with an enhanced software that will boost their imaging capabilities. Credit: StockSnap / Pixabay.

US-based medical device start-up Exo has raised $40m in a Series B extension funding to support the development of its hand-held ultrasound device.

The round was led by Magnetar Capital affiliates Fiscus Ventures and Reimagined Ventures together with Action Potential Venture Capital. Solasta Ventures, TDK Ventures, and all existing investors, including Intel Capital and Applied Ventures also participated in the round.

In addition to funding the development of its ultrasound product, Exo intends to use the proceeds from the round to roll out its data and workflow apps to the market.

The company’s handheld ultrasound device uses patented piezoelectric micromachined ultrasound transducer technology.

Exo is pairing the device with workflow apps to provide hospitals and clinics with enhanced software that will boost imaging capabilities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Exo CEO Sandeep Akkaraju said: “Emergency room physicians around the world are often tasked with solving some of the most urgent healthcare problems – Covid-19 diagnosis and complications, cardiac emergencies, internal bleeding – without being able to see clearly into a patient they only have minutes to diagnose and treat.

“Exo plans to give these critical frontline heroes the device they need – one that immediately opens up a window into everybody and enables them to make speedy, accurate and often life-saving medical decisions on the spot.”

According to reports, the latest funding brings the total capital raised by the company to nearly $100m. Last year, the company secured $35m through its initial Series B funding.

In a separate development, ophthalmic medical device company LensGen has reported the initial closing of the $10m bridge financing.

The financing is part of the company’s upcoming Series B round that will support its efforts for the approval of Juvene intraocular lens (IOL) pivotal Food and Drug Administration (FDA) study.

Juvene is a disruptive fluid-optic IOL for the treatment of cataract and presbyopia diseases.